RELEASE ISSUED BY: ECOG-ACRIN CANCER RESEARCH GROUP
September 28, 2015—VIENNA and PHILADELPHIA and REDWOOD CITY, Calif.)—Initial results were announced today from the Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer ...read more
INI1-road against HIV—More than 35 million individuals worldwide are living with HIV, and drug resistance to various available treatments is prevalent because of the virus’ extremely high mutation rate. The National Institute of General Medical Services has awarded Ganjam Kalpana, Ph.D., nearly $1.3 million over four years to study potential drug targets for HIV and develop inhibitors for these... read more
Preventing HIV Infection—The NIH has awarded Viraj Patel, M.D., MPH a career development award of nearly $1 million over five years to develop tools for preventing HIV infection in young men of color who have sex with men (YMCSM). As this population has the highest rates of new HIV infections in the U.S., Dr. Patel plans to partner with YMCSM peer... read more
Identifying New Treatment Targets—The National Institute of Allergy and Infectious Disease has awarded Felipe Diaz-Griffero, Ph.D. $2.7 million over five years, to study the molecular mechanisms that govern HIV-1 viral capsid “uncoating”—a key step allowing HIV-1 (the virus that causes AIDS) to infect cells. Dr. Diaz-Griffero has identified the capsid as a novel target to prevent HIV-1 infection and... read more
Two recent studies from Einstein-Montefiore faculty spotlight the benefits of the intrauterine device (IUD), an extremely effective contraceptive that is underused by American women.
Dr. Shamoon represents Einstein and Montefiore Medical Center in the NIH’s Clinical and Translational Science Award Consortium, an elite group ...read more